
Plexus (PLXS) Stock Forecast & Price Target
Plexus (PLXS) Analyst Ratings
Bulls say
Plexus Corp demonstrates a strong financial outlook, highlighted by a year-over-year revenue growth of 5% in its Healthcare Life Sciences segment, amounting to $1.629 billion for the full year, with positive momentum expected to continue into the first quarter. The company anticipates high-single-digit to low-double-digit growth in its Healthcare Life Sciences for FQ1, driven by the ramping of multiple programs and recovering customer demand. Additionally, the anticipated growth in the Aerospace and Defense segment, alongside the overall company-wide revenue growth goal of 9-12%, reinforces Plexus's strong market position and potential for sustained earnings leverage.
Bears say
Plexus Corp's gross margin experienced a decline to 9.9% from 10.1% in the previous quarter, indicating potential pressure on profitability regardless of matching operating margins. Revenue from the Aerospace & Defense segment, representing 16% of total revenue, decreased by 6% both quarter-over-quarter and year-over-year, signaling demand weakness in a key market. The forecast for Industrial revenues suggests a projected decline in the first quarter, reflecting seasonality and moderating demand amid broader economic slowdown risks and challenges in maintaining competitive differentiation.
This aggregate rating is based on analysts' research of Plexus and is not a guaranteed prediction by Public.com or investment advice.
Plexus (PLXS) Analyst Forecast & Price Prediction
Start investing in Plexus (PLXS)
Order type
Buy in
Order amount
Est. shares
0 shares